The (-) enantiomers of 2',3'-dideoxy-5-fluoro-3'-thiacytidine [(-)-FTC] and 2',3'-dideoxy-3'-thiacytidine [(-)-BCH-189 or 3TC], nucleoside analogs with the unusual L configuration, were recently shown to have potent antiviral activity against human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) and hepatitis B virus in cell culture (2, 5, 8, 9, 12, 15, 33, 35, 36) . These antiviral agents are not cytotoxic in vitro and have a favorable pharmacological profile in animal models and in humans (32, 41) . Additional preclinical studies have demonstrated that the 5'-triphosphates of (-)-FTC and (-)-BCH-189 are competitive inhibitors of HIV-1 reverse transcriptase (RT) and are potent DNA chain terminators when HIV-1 RT is used (13, 35) . (-)-BCH-189 has progressed to phase I clinical trials, and studies with humans with (-)-FTC will be initiated soon.
The outcome of these studies will determine the ultimate value of these compounds for the prevention and treatment of HIV infection.
A growing concern in the evaluation of new antiretroviral agents is the possibility that drug-resistant HIV-1 variants will emerge in patients on therapy and limit clinical efficacy (26) . Several reports have documented the development of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT), 2',3'-dideoxyinosine (DDI), and 2',3'-dideoxycytidine (DDC) in patients on prolonged therapy with these nucleoside analogs (27, 38) . More recently, the development of HIV-1 resistance to nonnucleoside RT inhibitors has been observed both in vitro and in vivo (20, 21, 23, 27, 29) . Point mutations in the coding sequence of HIV-1 RT that confer the resistance to nucleosides and nonnucleoside inhibitors have been identified (26) . In several instances, characterization of drug-resistant viral variants that arise in cell culture with drug selection has helped to predict the likelihood of resistance and the types of resistant variants that develop in treated individuals (12, 18, 20, 21, 23, 27) . Since little information on HIV-1 resistance to oxathiolane-cytosine analogs is available, the studies presented in this report were undertaken to isolate and characterize HIV variants that are resistant to (-)-FTC and (-)-BCH-189.
MATERIALS AND METHODS
Chemicals. (-)-FTC, (-)-BCH-189, and their (+) congeners were synthesized in our laboratories as described previously (2, 6, 14) . The TIBO analog R82150 [(+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo [4, 5,1- ) with penicillin (50 IU/ml), streptomycin (50 ,ug/ml), L-glutamine (2 mM), HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer (10 mM), and 10% dialyzed fetal bovine serum (JRH Biosciences, Lenexa, Kans.). Stock preparations of HIV-1 (HTLV-IIIB strain; R. C. Gallo) were harvested from infected H9 cells by the shakeoff method (20) . Stock virus infectivity was determined by end-point dilution in PBM cells (HIV-1LAI) or in cells (HIV-1IIIB) as described previously (18, 38 passage. The cells were incubated with virus at a multiplicity of infection of 0.01 for 1 h before addition of the drug. After 1 week of incubation in 5% C02-air at 37°C, all the cells and media were removed from the flask and centrifuged at 700 x g for 5 min. The supematant (3 ml) was saved for RT activity determination and for preparation of a virus stock for drug susceptibility assays. The RT activity of the supernatant obtained from virus-infected drug-treated cells was compared with that from supernatant obtained from infected untreated cells at different weekly cycles, as described previously (37) . Half the cells and media were placed in a new flask containing uninfected mitogen-stimulated PBM cells, and fresh drug at the desired concentration was added. This procedure was repeated each week for a total of 8 weeks, except that at week 4, the (-)-FTC and (-)-BCH-189 concentrations were increased to 1 and 10 ,uM, respectively, and at week 6, the (-)-FTC concentration was increased to 10 ,uM. Virus stock from each weekly cycle was prepared by cell-free virus infection of human PBM cells, as described previously (37) .
(ii) In MT-2 cells. Selection of resistant virus in MT-2 cells was performed as previously described (20 Data analysis. The EC50 and median inhibitory concentrations were determined by the median effect method as described previously (7, 32) . Table 1 shows that week 7 viruses had become more than 1,000-fold resistant to both (-)-BCH-189 and (-)-FTC. Resistance to both compounds developed regardless of which had been used for initial selection, indicating cross-resistance between the compounds. Cross-resistance to the (+) enantiomers of BCH-189 and FTC was also evident (Table 1) , but crossresistance to DDC, DDI, AZT, FLT, TIBO R82150, or U-87201E was not present.
RESULTS
Resistant variants were also isolated by serial passage of virus in MT-2 cells in the presence of increasing concentrations of (-)-FTC (5 ,uM initially). Susceptibility testing demonstrated that after passage in 30 ,uM (-)-FTC, the virus was highly resistant to (-)-FTC (>300-fold) and crossresistant to (-)-BCH-189 (>50-fold) but remained suscepti- (Fig. 2) . The Met-184-to-Ile change was present in four of the five RT clones that were derived from infected cells after passage in 30 (Table 3) . However, only a threefold-decreased susceptibility to DDC-TP was noted. Moloney murine leukemia virus RT, which naturally encodes a Val at the position analogous to codon 184 of HIV-1 RT (1), was inherently resistant to FTC-TP and BCH-189-TP and thus behaved like the RT from (-)-FTC-and (-)-BCH-189-resistant viruses. No marked decrease in the susceptibility of the other three enzymes to AZT-TP and PFA compared with that of parental enzyme was noted (Table 3) . (1) a The median inhibitory concentration (IC50) was obtained with a poly(rI)n oligo(dC)18_24 template-primer for the three cytosine analogs as described in Materials and Methods. Poly(rA)n oligo(T)12_18 was used for the studies with AZT 5'-triphosphate (AZT-TP) and PFA. The experiment was performed in duplicate. The variability of the duplicates was less than 5%. The correlation coefficients for the data were .0.98.
3'-fluoro-DDC (5, 9, 35). However, unlike AZT, the oxathiolanes are not active against murine retroviruses. In the studies reported herein, HIV-1 resistant to (-)-FTC and (-)-BCH-189 emerged within seven weekly passages in human PBM cells at drug concentrations that can be achieved in vivo (31, 40) . However, when MT-2 cells were used, (-)-FTC-resistant HIV emerged after two passages in culture. This difference may be related to the higher initial selective concentration of (-)-FTC used in MT-2 cells as well as other factors.
Virus breakthrough was more apparent with (-)-BCH-189 than with (-)-FTC in human PBM cells exposed for 3 weeks to 0.1 ,uM drug (Fig. 1) . This finding is reminiscent of studies in CEM cells which showed that the antiviral activity of (-)-BCH-189 was completely abolished when virus was harvested after a longer incubation time, whereas the potency of (-)-FTC decreased only by a factor of about 10 (35). Table 1 ), suggesting that all these 3'-thiacompounds interact at the same site on the RT. The results also indicate that the (+) and (-) enantiomers interact in the same way and that there is no stereoselectivity at the binding site in relation to the oxathiolane ring. Interestingly, DDC, a compound structurally related to the oxathiolane nucleosides which contain an endocyclic 3'-methylene group instead of the 3'-thia-group, was not cross-resistant. (-)-FTC-and (-)-BCH-189-resistant viruses were also not cross-resistant to AZT, DDI, FLT, PFA, TIBO R82150, and U-87201E (Tables 1 and 2 (1) . The one reported exception to this is Moloney murine leukemia virus RT, which has a natural Val substitution present at the analogous position. Of interest, we have tested the activity of (-)-FTC against a Moloney murine leukemia virus-based recombinant retrovirus (39) and have found the 90% effective concentration to exceed 100 FtM (data not shown). In addition, the Moloney murine leukemia virus RT exhibited an 18-to 21-fold decreased susceptibility to FTC-TP and BCH-189 compared with that of wild-type HIV-1 RT, which was similar to the resistance seen with the RTs from FTC-and BCH-189-resistant viruses (Table 3 ). These findings, combined with the sequence derived from our resistant strains of HIV-1, strongly implicate the Met-184-to-Val or -Ile substitution in inducing resistance to FTC and (-)-BCH-189. Inhibition of resistant HIV-1 RT by DDC-TP was decreased by only threefold, suggesting that no substantial cross-resistance between DDC and FTC or BCH-189 would be found, which was the case in the antiviral studies (Tables 1 and 2) .
The "YMDD" (Tyr-Met-Asp-Asp) motif is considered diagnostic of retroviral RT (1, 4) . This sequence is a marker of key regions of secondary structure that fold to form the major part of the palm domain of RT, the major function of which is to hold a divalent metal ion (probably Mg2+) in position for a catalytic role. The Met-184 is in the very heart of' the active site where it has ample opportunity to interact with incoming nucleotides. The importance of the Met-184 in oxathiolane analog activity suggests that this class of compounds would be competitive inhibitors and chain terminators as has been previously shown with FTC-TP and BCH-189-TP (35) . It is conceivable that these compounds engage in some specific interaction with the Met-184 sulfur atom exploiting the hydrophobic character of sulfur. It is also important to note that both His and Met are known to engage in strong electronic chelating-type interactions with metal atoms. Thus, one cannot rule out a role for these residues which could contribute to the polymerization reaction indirectly by the metal ion. It is interesting that in (-)-FTC-or (-)-BCH-189-resistant RT, the Met-184 is changed to Val or Ile, which maintains the neutral polar character at that position of HIV-1 RT.
When Larder et al. introduced a Met-184-to-Leu substitution into HIV-1 RT by site-directed mutagenesis (19) (12) , whereas Boucher and colleagues in Holland recently reported that the Met-184-to-Ile change confers (-)-BCH-189 resistance (3). The position 184 mutation apparently confers modest (fivefold) resistance to DDI in vitro and also occurs in some patients undergoing DDI therapy (12) . Recently, Wainberg's group was able to select in MT-4 cells HIV-1 variants that are resistant to racemic BCH-189 (11) . These viruses were found to be cross-resistant to DDC and DDI. The authors reported that attempts to isolate resistant virus in primary human lymphocytes were not successful. In addition, the genetic basis for the resistance was not provided. At present, we cannot explain the discrepancy between this work and our data with the pure (-) enantiomer of BCH-189, which indicate no significant cross-resistance with DDC or DDI with virus selected in MT-2 and PBM cells. Thus, it appears that susceptibility of viruses to various nucleoside analogs may be dependent on the type of amino acid mutation at the 184 position and also on the technique and cell culture system used to select these viruses.
Of potential significance was the finding of the same Met-184-to-Val substitution in PBM cells from a patient who had been on (-)-BCH-189 treatment for a period of 4 months. This patient's CD4+ cell count markedly increased during the initial treatment phase but declined after 4 months to baseline levels, at which time treatment was discontinued.-Sequencing analysis demonstrated the presence of the Met-184-to-Val mutation in addition to the natural codon at position 184. The mixed nature of the isolate probably explains why the virus was still susceptible to (-)-BCH-189. Although these data are from only one patient, they suggest that the mutation conferring the genotype of resistance to (-)-BCH-189 can develop in vivo. The clinical consequence of the Met-184 mutation leading to (-)-BCH-189 resistance is still unclear. Sequential virus isolates from this patient indicate that the genotype reverts to the natural type within a few months. The development of the resistance mutation in vivo with (-)-BCH-189 therapy suggests that combination therapy designed to maximize antiviral effects while minimizing toxicity and diminishing the emergence of drugresistant strains should be considered for this drug (30) . The identification of the new Met-184-to-Val substitution arising in the presence of (-)-BCH-189 and (-)-FTC should permit effective patient monitoring for the development of resistance to these drugs and to design rational drug combinations. In addition, the novel oxathiolane nucleoside resistance mutation further extends the scope of RT mutations which are still compatible with enzyme function. This may help identify key combinations of drug resistance mutations that are lethal for enzyme activity.
